13C15N: glucagon-based novel isotope dilution mass spectrometry method for measurement of glucagon metabolism in humans

Background Glucagon serves as an important regulatory hormone for regulating blood glucose concentration with tight feedback control exerted by insulin and glucose. There are critical gaps in our understanding of glucagon kinetics, pancreatic α cell function and intra-islet feedback network that are...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Clinical proteomics Ročník 19; číslo 1; s. 16
Hlavní autori: Renuse, Santosh, Benson, Linda M., Vanderboom, Patrick M., Ruchi, F. N. U., Yadav, Yogesh R., Johnson, Kenneth L., Brown, Benjamin C., Peterson, Jane A., Basu, Rita, McCormick, Daniel J., Pandey, Akhilesh, Basu, Ananda
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London BioMed Central 19.05.2022
BioMed Central Ltd
Predmet:
Algorithms
Analysis
Biomedical and Life Sciences
Biotechnology
Blood sugar
Cell Biology
Diabetes therapy
Glucagon
Glucose tolerance tests
Insulin
Life Sciences
Mass spectrometry
Measurement
Methods
Pathology
Physiological aspects
Proteomics
Scientific equipment and supplies industry
Type 2 diabetes
United States
Oral glucose tolerance test
Stable isotope tracers
Type 1 diabetes
Insulin
ISSN:1542-6416, 1559-0275
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Background Glucagon serves as an important regulatory hormone for regulating blood glucose concentration with tight feedback control exerted by insulin and glucose. There are critical gaps in our understanding of glucagon kinetics, pancreatic α cell function and intra-islet feedback network that are disrupted in type 1 diabetes. This is important for translational research applications of evolving dual-hormone (insulin + glucagon) closed-loop artificial pancreas algorithms and their usage in type 1 diabetes. Thus, it is important to accurately measure glucagon kinetics in vivo and to develop robust models of glucose-insulin-glucagon interplay that could inform next generation of artificial pancreas algorithms. Methods Here, we describe the administration of novel 13 C 15 N heavy isotope-containing glucagon tracers—FF glucagon [(Phe 6 13 C 9 , 15 N; Phe 22 13 C 9 , 15 N)] and FFLA glucagon [(Phe 6 13 C 9 , 15 N; Phe 22 13 C 9 , 15 N; Leu 14 13 C 6 , 15 N; Ala 19 13 C 3 )] followed by anti-glucagon antibody-based enrichment and LC–MS/MS based-targeted assays using high-resolution mass spectrometry to determine levels of infused glucagon in plasma samples. The optimized assay results were applied for measurement of glucagon turnover in subjects with and without type 1 diabetes infused with isotopically labeled glucagon tracers. Results The limit of quantitation was found to be 1.56 pg/ml using stable isotope-labeled glucagon as an internal standard. Intra and inter-assay variability was < 6% and < 16%, respectively, for FF glucagon while it was < 5% and < 23%, respectively, for FFLA glucagon. Further, we carried out a novel isotope dilution technique using glucagon tracers for studying glucagon kinetics in type 1 diabetes. Conclusions The methods described in this study for simultaneous detection and quantitation of glucagon tracers have clinical utility for investigating glucagon kinetics in vivo in humans.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1542-6416
1559-0275
DOI:10.1186/s12014-022-09344-2